Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.55 |
| ▸ | AKT1 | P31749 | 3/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12928154 | 0.80 | PIK3CA (0.60) | PIK3CAAKT1MAP4K4 | |
| SCHEMBL12928159 | 0.79 | PIK3CA (0.59) | PIK3CAAKT1MAP4K4 | |
| SCHEMBL12928144 | 0.78 | PIK3CA (0.54) | PIK3CAAKT1ACVR1MAPK10MAP4K4 | |
| SCHEMBL10156122 | 0.77 | PIK3CA (0.71) | PIK3CAAKT1MAPK10MAP4K4 | |
| SCHEMBL730195 | 0.76 | PIK3CA (0.84) | PIK3CAAKT1ACVR1MAPK10MAP4K4 | |
| SCHEMBL730188 | 0.74 | PIK3CA (0.87) | PIK3CAAKT1ACVR1MAPK10MAP4K4 | |
| SCHEMBL3653172 | 0.72 | PIK3CA (0.63) | PIK3CAAKT1ACVR1MAPK10 | |
| SCHEMBL19219069 | 0.71 | PIK3CA (0.71) | PIK3CAAKT1ACVR1CA12CA1 | |
| SCHEMBL12928157 | 0.71 | PIK3CA (0.62) | PIK3CAAKT1MAP4K4 | |
| SCHEMBL27898092 | 0.71 | PIK3CA (0.65) | PIK3CAACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| WO-2014151147-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011022439-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 8/4885ACVR1 2026/4885 |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | PIK3C3, ERBB3, ERBB2 | PIK3CA 7/4885AKT1 14/4885ACVR1 537/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 8/4885ACVR1 2026/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 8/4885ACVR1 2026/4885 |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, PIK3CA, AKT1 | PIK3CA 2/4885AKT1 3/4885ACVR1 1417/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 8/4885ACVR1 2026/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | PIK3CA 4/4885AKT1 10/4885ACVR1 2369/4885 |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 8/4885ACVR1 2026/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | PIK3CA 6/4885AKT1 5/4885ACVR1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.